Status:
TERMINATED
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
Lead Sponsor:
Medivation, Inc.
Collaborating Sponsors:
Pfizer
Conditions:
Moderate to Severe Alzheimer
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.
Eligibility Criteria
Inclusion
- Moderate-to-Severe Alzheimer's disease
- Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive
- Stable on donepezil for at least 6 months
Exclusion
- Other causes of dementia
- Major structural brain disease
- Unstable medical condition or significant hepatic or renal disease
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT00954590
Start Date
October 1 2009
Last Update
September 27 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Santiago, Chile
2
Glasgow, Scotland, United Kingdom